Pharmacogenetic Predictors of Outcome in Patients with Stage II and III Colon Cancer Treated with Oxaliplatin and Fluoropyrimidine-Based Adjuvant ChemotherapyAna Custodio, Jaime Feliú, Juan Moreno‐Rubio et al.|Molecular Cancer Therapeutics|2014Cited by 12
Towards Defining Follow-up Strategies for Patients with Primary Intermediate-risk Non–muscle-invasive Bladder CancerRoberto Contieri, Jaromír Háček, Alberto Martini et al.|European Urology Oncology|2025Cited by 11
[Pseudotumorous cardiac infiltration in a patient with acute monoblastic leukemia].María Orts, Evarist Feliú, Josep‐María Ribera et al.|PubMed|1996Cited by 9
Pharmacogenetic predictors of adverse events in stage II-III colon cancer (CC) patients treated with oxaliplatin and fluoropyrimidines-based adjuvant chemotherapy (CT): A GEMCAD study.Ana Custodio, Juan Antonio Moreno, Jorge Aparicio et al.|Journal of Clinical Oncology|2012Cited by 0
Data Supplement from Pharmacogenetic Predictors of Outcome in Patients with Stage II and III Colon Cancer Treated with Oxaliplatin and Fluoropyrimidine-Based Adjuvant ChemotherapyAna Custodio, Jaime Feliú, Juan Moreno‐Rubio et al.|Unknown|2023Cited by 0